- Immunosuppressive therapies and biologics, such as rituximab and corticosteroids, are increasingly vital components of membranous nephropathy treatment in the U.S., driven by their effectiveness in reducing proteinuria and preserving kidney function in patients with moderate to severe disease. These advanced therapeutics are becoming standard in both hospital-based nephrology care and specialized outpatient clinics
- The escalating demand for targeted treatment options is primarily fueled by the rising prevalence of autoimmune conditions and chronic kidney disease across the U.S., coupled with increasing awareness among healthcare providers and patients regarding early detection and personalized disease management strategies
- U.S. accounted for 41.3% market share in membranous nephropathy market in 2024 within the global landscape, supported by a robust healthcare infrastructure, early adoption of novel therapeutics, and substantial R&D investments by pharmaceutical companies focused on rare renal diseases
- The treatment segment dominated the membranous nephropathy market with a market share of 72.3% in 2024, driven by the widespread use of immunosuppressive therapies and biologics such as rituximab. The increasing clinical adoption of targeted treatments and advancements in therapeutic protocols continue to reinforce the dominance of this segment in managing both primary and secondary membranous nephropathy
